Ariana Boswell

All articles by Ariana Boswell

• Germinal centers may mean poor outcomes in thymoma-associated MG

  A study of patients with thymoma-associated MG found that germinal centers in the thymic tissue lower the incidence of minimal manifestations.

• Efgartigimod found safe, effective in small-scale study of children with MG

  A retrospective analysis of 17 children with juvenile MG in China supports the safety and efficacy of efgartigimod.

• Telitacicept found safe and effective in older adults with MG

  Older adults with MG who receive telitacicept as an add-on therapy experience improvements in symptoms and disease biomarkers, a study found.

• Efgartigimod found effective in ocular MG, argenx shares

  Findings from the phase 3 ADAPT OCULUS trial demonstrated the safety and efficacy of efgartigimod alfa and hyaluronidase-qvfc in ocular MG.

• How to ‘Light Up for Rare’ on Rare Disease Day

  Landmarks worldwide will light up on Rare Disease Day.

• What is a repetitive nerve stimulation test for myasthenia gravis?

  The test may create a feeling like static electricity or tingling, but shouldn’t be painful.

• What you should know about myasthenia gravis and pregnancy

  With careful monitoring from their medical team, those with MG can have a healthy pregnancy.

• New antibody-targeting drug may hold promise in MG

  Researchers identified a novel drug that can break down antibodies against the acetylcholine receptor, which are prevalent in people with MG.

• CNP-106 receives Orphan Drug Designation for MG

  CNP-106 works by downregulating overactive immune responses in patients with generalized MG caused by anti-AChR antibodies.

• Unexpected side effects linked to efgartigimod alfa use in MG

  A recent study identified adverse events attributed to efgartigimod alfa use that are not currently listed in the drug’s manual.